Paroxetine was effective for reducing symptoms in social phobia


QUESTION: In patients with social phobia, is paroxetine effective for reducing symptoms?

Design
Randomised [allocation concealed*†, blinded [clinicians, patients, outcome assessors, and statisticians]*‡, placebo controlled trial with 12 week follow up.

Setting
39 centres in Belgium, France, Germany, Ireland, South Africa, Spain, and the United Kingdom.

Patients
290 patients who were ≥18 years of age (mean age 36 y, 54% women) and had a primary diagnosis of social phobia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria. Exclusion criteria included any other recent Axis I disorder, serious medical disorders, or recent use of psychotropic drugs or psychotherapy. 75% of patients completed the study, and 97% were analysed.

Intervention
Patients were allocated to paroxetine, 20 mg/day initially and increased by 10 mg/day as needed to a maximum of 50 mg/day (mean dose 34.7 mg/d) (n = 139), or to placebo (n = 151) for 12 weeks.

Outcome Paroxetine v placebo for social phobia at 12 weeks

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Paroxetine</th>
<th>Placebo</th>
<th>RBI (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment response</td>
<td>66%</td>
<td>32%</td>
<td>103% (57 to 166)</td>
<td>4 (3 to 5)</td>
</tr>
</tbody>
</table>

Main outcome measures
Mean change in scores on the Liebowitz Social Anxiety Scale (LSAS, maximum score 144 points) and the proportion of responders on the Clinical Global Impression (CGI) scale (maximum score 7 points). Secondary outcomes included the score on the Social Avoidance and Distress Scale (maximum score 28 points).

Main results
More patients in the paroxetine group than in the placebo group were treatment responders (p < 0.001) (table). Paroxetine led to greater improvement from baseline than did placebo in scores on the LSAS (difference in mean change from baseline 13.8, 95% CI 6.1 to 21.5)‡ and the Social Avoidance and Distress Scale (difference in mean change from baseline 3.3, 1.4 to 5.3)‡ and the CGI (difference in mean change from baseline 0.7, CI 0.4 to 1.0)‡.

Conclusion
In patients with social phobia, paroxetine was effective for reducing symptoms.

COMMENTARY
Social phobia is a situationally linked, intense, irrational, persistent fear of being scrutinised or negatively evaluated by others1 and is associated with fear of humiliation or embarrassment.2 Thus, socially demanding situations become disabling. Patients are cognitively aware of the irrationality of their fear. Prevalence rates are about 13% for lifetime3 and 7% at 1 year.4 The presence of social phobia increases the risk for mental, drug, and alcohol comorbid illnesses.5 If the condition remains untreated, it can become chronic and unremitting, leading to education and employment difficulties.6

Cognitive behaviour therapy with or without antidepressants is the most effective treatment.1 However, properly administered therapy is not available, affordable, or obtainable for most people with social phobia. Current drug options are selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors, and benzodiazepines. Little evidence exists for the effectiveness of tricyclic antidepressants.7

The study by Baldwin and colleagues and the current deluge of consumer education and marketing illuminate this hidden, underdiagnosed anxiety disorder. A crossover design would yield even more information and would perhaps address the effects after 12 weeks of treatment or after discontinuation. As is often the case, the sample was selected: patients had pure social phobia, no comorbid conditions, and no history of failed SSRI therapy for any illness. Excluding previous non-responders biases the results toward SSRI efficacy. This luxury does not exist in the office where initial treatment occurs. However, the overall results of this study support using paroxetine to treat social phobia initially; other data also support using other SSRIs and treatments.1 The main message is the importance of recognising and diagnosing this under recognised, debilitating illness because of the tremendous implications for quality of life.

Stephen A Wilson, MD
University of Pittsburgh Medical Center, St. Margaret Pittsburgh, Pennsylvania, USA

Source of funding: SmithKline Beecham Pharmaceuticals.

For correspondence:
Dr D Baldwin, Mental Health Group, University of Southampton, Royal South Hants Hospital, Brintons Terrace, Southampton SO14 0YG, UK. Fax +44 (0)1703 234243.

Paroxetine was effective for reducing symptoms in social phobia

*Evid Based Med* 2000 5: 86
doi: 10.1136/ebm.5.3.86

Updated information and services can be found at:
http://ebm.bmj.com/content/5/3/86

**These include:**

**References**
This article cites 3 articles, 1 of which you can access for free at:
http://ebm.bmj.com/content/5/3/86#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Anxiety disorders (including OCD and PTSD) (27)
- Drugs: musculoskeletal and joint diseases (349)
- Clinical trials (epidemiology) (1594)
- Drugs: CNS (not psychiatric) (262)
- Psychotherapy (47)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/